Weizmann Institute of Science
Israel's basic research institute, whose HER receptor, p53, single-cell immunology and microbiome discoveries have shaped cancer biology.
Founded in 1934 as the Daniel Sieff Institute, the Weizmann Institute of Science created the Moross Integrated Cancer Center in 2016 to link its cancer groups with clinical partners. Yosef Yarden's work on ErbB/HER receptor signalling and antibody combinations, Moshe Oren and Varda Rotter's on p53, Ido Amit's single-cell immunology of tumour myeloid cells, Eran Elinav's microbiome studies and Yardena Samuels's neoantigen discovery in melanoma are widely cited, and Michael Sela's group's early work on combining anti-EGFR antibodies with chemotherapy underpinned patents relevant to cetuximab. The institute's Yeda technology transfer arm has licensed numerous cancer diagnostics and therapeutics, and its scientists collaborate with Sheba, Rambam and international centres.
- Moross Integrated Cancer Center
- HER receptor and antibody biology
- p53 biology
- Single-cell immunology
- Microbiome and cancer
Pages like this
not linked directly; found by shared links- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Proteomics & phosphoproteomics, Neoantigen, Acute myeloid leukaemia, Melanoma.
- InstitutionIstituto di Candiolo IRCCS – FPO
Shares Monoclonal antibodies, HER2, EGFR, HER2-positive breast cancer.
- CompanyElucidate Bio
Shares Proteomics & phosphoproteomics, Single-cell & spatial profiling.
- InstitutionMax Delbrück Center for Molecular Medicine
Shares CRISPR functional genomics, Single-cell & spatial profiling, Melanoma, Colorectal cancer.
- InstitutionIstituto Oncologico Veneto IRCCS
Shares Monoclonal antibodies, HER2-positive breast cancer, Melanoma, Colorectal cancer.
- InstitutionRosalind and Morris Goodman Cancer Institute, McGill University
Shares HER2, HER2-positive breast cancer, Melanoma, Colorectal cancer.
- InstitutionHospital del Mar / Hospital del Mar Research Institute
Shares Monoclonal antibodies, HER2, HER2-positive breast cancer, Colorectal cancer.
- ProductTrastuzumab biosimilars
Shares Monoclonal antibodies, HER2, HER2-positive breast cancer.